adverum.com Open in urlscan Pro
35.203.171.134  Public Scan

Form analysis
1 forms found in the DOM

GET https://adverum.com/

<form role="search" method="get" class="et-search-form" action="https://adverum.com/">
  <input type="search" class="et-search-field" placeholder="Search …" value="" name="s" title="Search for:">
</form>

Text Content

 * 
 * 
 * 

Redefining Sight for Life.
 * About Us
   * Our Global Mission
   * Core Values
   * Sustainability
   * Leadership Team
   * Board of Directors
   * Scientific Advisors
   * Board Committees
 * Our Technology
   * Reimagining Ocular Gene Therapy
   * Therapeutic Protein Biofactories
   * Sustained Protein Expression
   * Efficient, Scalable Manufacturing
 * Pipeline
   * Our Programs
   * Ixo-vec
 * For Patients & Caregivers
   * Overview
   * Resources
   * Our Commitment
 * Join The Team
   * Life at Adverum
   * Our Credo
   * Our Benefits
   * Diversity, Equity, and Inclusion
   * Careers
 * News & Publications
   * In the News
   * Publications
 * Contact Us
 * Investors
   * Overview
   * News
   * Events & Presentations
   * Stock Info
   * Financials
   * Governance
   * Resources

Scroll to top
Contact Us




SEE LIFE.


IN VISION.


IN ACTION.


IN EXPRESSION.

REDEFINING SIGHT FOR LIFE.

We aspire to develop functional cures through gene therapy to restore vision and
prevent blindness.






SO YOU SEE.


LIFE.


OUR GLOBAL MISSION

To establish gene therapy as a new standard of care for the leading causes of
vision loss.

LEARN MORE



FOR PATIENTS AND CAREGIVERS

Adverum aims to establish gene therapy as a new standard of care for a number of
highly prevalent ocular diseases with the aspiration of developing functional
cures for these diseases to restore vision and prevent blindness. Our lead
program is in wet age-related macular degeneration (wet AMD), which is growing
as the leading cause of blindness globally, driven by aging populations combined
with treatment options that do not effectively stave off blindness in real-world
use. The current standard of care consists of painful eye injections (anti-VEGF
therapies) delivered by a retinal specialist recurring every 4-8 weeks. Patients
undergoing this burdensome treatment regime often miss treatments, putting them
at increased risk of losing their sight. Adverum’s investigational gene therapy
Ixo-vec is being developed to offer an in-office, single-administration
intravitreal (IVT) therapy with the potential to extend treatment benefit from
weeks to years.
LEARN MORE

OUR TECHNOLOGY

Using our proprietary, next-generation adeno-associated virus (AAV) vector
platform, we are developing Ixo-vec as a long-lasting treatment for wet AMD.
Ixo-vec is a vectorized therapeutic protein (aflibercept) treatment designed to
transform retinal cells into ocular biofactories that continually produce and
dispense therapeutic doses of aflibercept, a proven effective anti-VEGF
treatment.
LEARN MORE


WE SEE BEYOND

Adverum aspires to transform the standard of care, preserve long-term vision,
and create a profound societal impact around the globe, by advancing gene
therapies for highly prevalent ocular diseases. Leveraging the research
capabilities of our IVT platform, we design durable medicines that can be
administered in the physician’s office, eliminate the need for frequent retinal
injections, in an effort to greatly improve accessibility to treatment.



Dr. Laurent Fischer

President and Chief Executive Officer

NEWS & PUBLICATIONS

NEWS & PRESS RELEASES

View All

ADVERUM BIOTECHNOLOGIES REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS

News November 10, 2022

ADVERUM BIOTECHNOLOGIES PRESENTS POSITIVE END OF STUDY RESULTS FROM THE OPTIC
TRIAL IN WET AMD INCLUDING TWO-YEAR OUTCOMES FOLLOWING A SINGLE INTRAVITREAL
INJECTION OF IXO-VEC (ADVM-022) READ MORE

News November 4, 2022

ADVERUM BIOTECHNOLOGIES ANNOUNCES UPCOMING DATA PRESENTATION AT THE RETINA
SOCIETY ANNUAL MEETING READ MORE

News October 27, 2022

ADVERUM BIOTECHNOLOGIES PRESENTS ANATOMICAL IMPROVEMENTS IN INTRARETINAL AND
SUBRETINAL FLUID AFTER A SINGLE IVT INJECTION OF IXO-VEC (ADVM-022) IN THE OPTIC
STUDY IN WET AMD READ MORE

News September 30, 2022

ADVERUM BIOTECHNOLOGIES TO PARTICIPATE IN THE CHARDAN 6TH ANNUAL GENETIC
MEDICINES CONFERENCE READ MORE

News September 27, 2022

PUBLICATIONS

View All

RETINA SOCIETY 2022

Presentations November 4, 2022

AAO 2022

Presentations September 30, 2022

ASRS 2022

Presentations July 13, 2022

MACULA SOCIETY ANNUAL MEETING

Presentations June 8, 2022

ASGCT 2022

Presentations May 19, 2022


CONTACT US

Interested in learning more and getting an inside view of Adverum? We are eager
to hear from you. Please complete our contact form to engage with one of our
team members.

CONTACT US
We are driven to establish gene therapy as a new standard of care for the
leading causes of vision loss.
 * 
 * 
 * 

ABOUT US

 * About Us
 * Our Global Mission
 * Core Values
 * Sustainability
 * Leadership Team
 * Board of Directors
 * Scientific Advisors
 * Board Committees

OUR TECHNOLOGY

 * Our Technology
 * Reimagining Ocular Gene Therapy
 * Therapeutic Protein Biofactories
 * Sustained Protein Expression
 * Efficient, Scalable Manufacturing

PIPELINE

 * Pipeline
 * Our Programs
 * Ixo-vec

FOR PATIENTS & CAREGIVERS

 * For Patients & Caregivers
 * Overview
 * Resources
 * Our Commitment

INVESTORS

 * Investors
 * Overview
 * News
 * Events & Presentations
 * Stock Info
 * Financials
 * Governance
 * Resources

JOIN THE TEAM

 * Join The Team
 * Life at Adverum
 * Our Credo
 * Our Benefits
 * Diversity, Equity, and Inclusion
 * Careers

NEWS & PUBLICATIONS

 * News & Publications
 * In the News
 * Publications

SEEING BEYOND BLOG

CONTACT US

 * Contact Us

Privacy PolicyCommunity Guidelines

ADVERUM

Adverum Biotechnologies, Inc.,
100 Cardinal Way, Redwood City, CA 94063

Tel: 650-656-9323Fax: 650.649.1995

©Adverum Biotechnologies, Inc. All rights reserved.
 * Privacy Policy
 * Community Guidelines